Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated α-synuclein
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Parkinson's disease is a neurodegenerative disorder characterized by motor and non-motor disturbances. Various pathogenic pathways drive disease progression including oxidative stress, mitochondrial dysfunction, α-synuclein aggregation and impairment of protein degradation systems. Dysfunction of the ubiquitin-proteasome system in the substantia nigra of Parkinson's disease patients is believed to be one of the causes of protein aggregation and cell death associated with this disorder. Lactacystin, a potent inhibitor of the proteasome, was previously delivered to the nigrostriatal pathway of rodents to model nigrostriatal degeneration. Although lactacystin-treated animals develop parkinsonian motor impairment, it is currently unknown whether they also develop non-motor symptoms characteristic of this disorder. In order to further describe the proteasome inhibition model of Parkinson's disease, we characterized the unilateral lactacystin model, performed by stereotaxic injection of the toxin in the substantia nigra of mice. We studied the degree of neurodegeneration and the behavioral phenotype 1 and 3 weeks after lactacystin lesion both in terms of motor impairment, as well as non-motor symptoms. We report that unilateral administration of 3 μg lactacystin to the substantia nigra of mice leads to partial (~40%) dopaminergic cell loss and concurrent striatal dopamine depletion, accompanied by increased expression of Ser129-phosphorylated α-synuclein. Behavioral characterization of the model revealed parkinsonian motor impairment, as well as signs of non-motor disturbances resembling early stage Parkinson's disease including sensitive and somatosensory deficits, anxiety-like behavior, and perseverative behavior. The consistent finding of good face validity, together with relevant construct validity, warrant a further evaluation of proteasome inhibition models of Parkinson's disease in pre-clinical research and validation of therapeutic targets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653 · cited 2×
“…et al., 2004; Bukhatwa et al., 2010), loss of 19S regulatory particles, including the proteasomal activator PA700 (McNaught et al., 2003; Grunblatt et al., 2004), as well as a general loss of all three peptidase activities of the 20S proteasome (McNaught and Jenner, 2001; Tofaris et al., 2003).”
BackgroundAltered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573 · cited 6×
“In order to further describe the proteasome inhibition model of Parkinson’s disease, we characterized the unilateral lactacystin model, performed by stereotaxic injection of the toxin in the substantia nigra of mice.”
BackgroundInfluentialTofaris, G. K., Layfield, R., & Spillantini, M. G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03115-5 · Cited by 363
Oliveras-Salvá, M., Van der Perren, A., Casadei, N., Stroobants, S., Nuber, S., D’Hooge, R., Van den Haute, C., & Baekelandt, V. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-44 · Cited by 191 · cited 1×
“…α-synuclein in the SN of rats or mice have been developed that display α-synuclein aggregation and dopaminergic cell death (Lauwers et al., 2007; Oliveras-Salva et al., 2013; Van der Perren et al., 2015), there is still an important need for the characterization of novel models of sporadic…”
BackgroundSelf-citationNonmotor versus motor symptoms: How much do they matter to health status in Parkinson's disease?
Hinnell, C., Hurt, C. S., Landau, S., Brown, R. G., Samuel, M., & on behalf of the PROMS‐PD Study Group (2012) · Movement Disorders · doi:10.1002/mds.23961 · Cited by 142 · cited 1×
“…a series of non-motor symptoms, such as anxiety, depression, somatosensory dysfunction, or cognitive impairment (Chaudhuri and Schapira, 2009; Martinez-Martin and Damian, 2010; Conte et al., 2013) that have a significant impact on the quality of life (Martinez-Martin, 2011; Hinnell et al., 2012).”
Background
Cited by
Lastres-Becker, I., García-Yagüe, A. J., Scannevin, R. H., Casarejos, M. J., Kügler, S., Rábano, A., & Cuadrado, A. (2016) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6549 · Cited by 274
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“Intracerebral proteasome inhibitor infusion evokes a preferential degeneration of nigrostriatal DA neurons, accompanied by the onset of PD-associated motor impairments (Bentea et al. 2015; Fornai et al. 2003; Li et al. 2012).”
BackgroundSzego, E. M., Malz, L., Bernhardt, N., Rösen-Wolff, A., Falkenburger, B. H., & Luksch, H. (2022) · eLife · doi:10.7554/elife.81943 · Cited by 94
“Based on findings with other mouse models of PD by ourselves and others (Bentea et al., 2015; Gong et al., 2019; OliverasSalvá et al., 2013), we do not expect a dopaminedependent motor phenotype in these mice.”
BackgroundCortical phosphorylated α‐Synuclein levels correlate with brain wave spectra in Parkinson's disease
Caviness, J. N., Lue, L., Hentz, J. G., Schmitz, C. T., Adler, C. H., Shill, H. A., Sabbagh, M. N., Beach, T. G., & Walker, D. G. (2016) · Movement Disorders · doi:10.1002/mds.26621 · Cited by 37
Konieczny, J., Lenda, T., & Czarnecka, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.072 · Cited by 12
Metadata
- Authors
- Bentea, E., Van der Perren, A., Van Liefferinge, J., El Arfani, A., Albertini, G., Demuyser, T., Merckx, E., Michotte, Y., Smolders, I., Baekelandt, V., & Massie, A.
- Venue
- Frontiers in Behavioral Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2015-03-31
- Volume
- 9
- Pages
- 68-68
- ISSN
- 1662-5153 (ISSN-L)
- OpenAlex
- W2089578389
- Cited by
- 54
- References
- 7
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.